EN DE
Watch Hikal Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hikal Limited (HIKAL) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Hikal Limited stock ₹23.70, price ₹217, that is 89.1% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE475B01022

HL Hikal Limited logo Thin data Nov 11, 2026

Hikal Limited

HIKAL · NSE

Far too expensive (fair value 89% below the price), weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Generates free cash flow 
Last quarter vs. a year ago: revenue +36%, profit +68%. 
Quality 42/100 
Price moving sideways (no uptrend) 
Fair value ₹23.70 · Strongly overvalued 
Weak Growth (revenue 5y +0.1 %/yr in INR) 
Loss-making · -0.3% net margin (TTM) 
Trails peers (3/13) 
Narrow moat 18/100
Thin data 
Extreme value
Watch Hikal Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹696.69 ₹146.84 Fair Value ₹23.70 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range ₹146.84 – ₹696.69 · fair‑value band ₹23.70 – ₹43.21 · the ₹216.58 price screens above the ₹23.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.

Follow Hikal in your weekly email

Every Wednesday you see whether Hikal is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries.

Show moreShow less

It operates through two segments, Pharmaceuticals and Crop Protection.

The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients.

Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries.

The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000.

Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

Stock analysis

Hikal Limited (HIKAL) currently trades at ₹216.58, while our model-based Fair Value estimate is ₹23.70, 89% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of ₹75.41 per share, and 0 of the 14 models we run sit above the ₹216.58 price.

Bear case: the Multiples group reads lowest at ₹23.70, and 14 of the 14 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹23.70 (bear) to ₹43.21 (bull), the price of ₹216.58 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.

Hikal Limited reported revenue of ₹17.1B in FY2026 versus ₹19.3B in FY2022, a compound −2.9%/yr. Reported net income was −₹488M in FY2026.

Key figures

Market cap ₹26.7B (≈ $284M) Micro · P/E ex one-offs 629.8 · P/S ratio 1.48 · EPS (TTM) ₹−2.74 · Dividend yield 0.4% · Net margin −0.3% · Return on equity −0.4% · Return on assets (EBIT) 11.3% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).

What moves the price

The share trades about 15% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −89%, HIKAL screens richer than that median.

Fair Value models

Bear ₹23.70 Fair Value ₹23.70 Bull ₹43.21
Price ₹216.58 · Downside -89.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF ₹58.29 ₹87.34 ₹121.49 81
Growth DCF ₹58.33 ₹83.52 ₹111.48 79
Owner Earnings ₹19.24 ₹35.32 ₹54.21 75
All 14 models by family
DCF Models
FCF DCF ₹58.29 ₹87.34 ₹121.49 81
Owner Earnings ₹19.24 ₹35.32 ₹54.21 75
5Y Revenue Exit ₹32.71 ₹54.67 ₹80.94 72
5Y EBITDA Exit ₹99.04 ₹177.10 ₹266.96 74
10Y Revenue Exit ₹43.22 ₹63.47 ₹87.94 67
10Y EBITDA Exit ₹78.01 ₹131.46 ₹200.82 67
Earnings-Based
EPV n/a ₹0.6900 >₹2.76 68
Multiples
EV/EBIT ₹4.19 ₹23.70 ₹43.21 58
EV/EBITDA ₹133.35 ₹195.91 ₹258.47 66
EV/Revenue n/a ₹5.34 >₹21.36 50
Asset-Based
NCAV (Graham) ₹48.38 ₹64.83 ₹96.76 54
Growth DCF
Growth DCF ₹58.33 ₹83.52 ₹111.48 79
Rev-Margin DCF ₹32.71 ₹56.29 ₹83.61 72
Economic Profit
ROIC Compounder n/a ₹0.6900 >₹2.76 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 21
How much profit the company makes from its sales and capital
Quality Growth 9
Are margins and returns getting better?
Cashflow 31
Do the profits arrive as real cash?
Financial strength 49
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 59
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 45
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 23/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−7.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.1%
Start year 2021 (pandemic). Over 10 years: +6.5% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
13.4% (2021) → 3.3% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +26.5% a year for the price.

HIKAL screens overvalued: fair value 89% below the price. Compare with Merck KGaA →

Compare Hikal Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Below median
Fair Value upside −89.1% · Bottom 25%
Profitability
Return on assets −2.1% · Below median
Net margin (12 months) −0.3% · Below median
Operating margin (12 months) 0.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 36.3% · Top 25%
Dividend yield (12 months) 0.4% · Bottom 25%
Balance sheet
Debt / equity 0.31× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 2.23× · Pricier than median
P/S (12 months) 1.44× · Cheaper than median
Price / free cash flow (fiscal year) 29.9× · Pricier than median
EV/EBITDA 11.3× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)0 · sector 26
HEALTH (low debt)84 · sector 96
DIVIDEND (yield)9 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs HIKAL
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs HIKAL
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs HIKAL
Haleon plc HLN $9.20 $8.47 −8% vs HIKAL
Merck KGaA MRK €149.70 €108.83 −27% vs HIKAL
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs HIKAL
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs HIKAL
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs HIKAL
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs HIKAL
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs HIKAL

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hikal Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hikal Limited Fair Value". https://www.fairvalue-calculator.com/stock/HIKAL

Frequently asked questions

Is Hikal Limited (HIKAL) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of ₹23.70 versus a price of ₹216.58, about 89% lower (overvalued).
What is the fair value of HIKAL?
Our model-based fair value for Hikal Limited is ₹23.70 (as of Nov 11, 2026), built from audited fundamentals. The current price: ₹216.58.
What is the quality score of HIKAL?
Hikal Limited has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hikal Limited (HIKAL)?
Our model-based price target is the fair value of ₹23.70 (as of Nov 11, 2026) from 14 valuation models. Cautious scenario ₹23.70, optimistic scenario ₹43.21. It is a calculation from audited fundamentals, not an analyst target.
What is the Hikal Limited stock forecast for 2026?
Our models put fair value at ₹23.70, about 89% lower versus a price of ₹216.58 (overvalued). Cautious scenario ₹23.70, optimistic scenario ₹43.21. The calculation is refreshed regularly with new filings.
What is the revenue of Hikal Limited (HIKAL)?
Hikal Limited reported trailing-twelve-month revenue of about ₹18.5B (latest available figure, as of Nov 11, 2026).
Does Hikal Limited pay a dividend?
Hikal Limited currently shows a dividend yield of 0.45% relative to its recent price (as of Nov 11, 2026).
How much is the dividend of Hikal Limited (HIKAL)?
Hikal Limited has a dividend yield of 0.4%.
What growth is priced into Hikal Limited (HIKAL)?
For today's price to be fair in a discounted-cash-flow model, Hikal Limited would have to grow free cash flow by 31.8 % per year for five years (discount rate 13.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 0.1 % per year. As of Nov 11, 2026.
What discount rate (WACC) does the fair value of HIKAL use?
Our models discount Hikal Limited at 13.9 %: a base by market capitalisation (micro), damped by beta 0.53, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hikal Limited that is +31.8 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.9 %) and the same formula as our fair value.
How much growth has Hikal Limited (HIKAL) delivered so far?
Over the past 5 years revenue at Hikal Limited grew 0.1 % a year. The price currently implies free-cash-flow growth of +31.8 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hikal Limited (HIKAL) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Hikal Limited (+31.8 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hikal Limited (HIKAL)?
The free-cash-flow yield on the price is 3.34 %: that much free cash flow Hikal Limited produces per unit of market value. When it exceeds the discount rate of our models (13.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hikal Limited (HIKAL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hikal Limited it is ₹23.70 per share (as of Nov 11, 2026), against a price of ₹216.58. It is the blended result of 14 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Hikal Limited stock overvalued or undervalued in 2026?
As of Nov 11, 2026, HIKAL trades above its calculated fair value: price ₹216.58, fair value ₹23.70, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HIKAL?
No. The price is what the market pays today (₹216.58); the fair value is what the company's own numbers justify (₹23.70). For Hikal Limited the two are ₹192.88 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hikal Limited worth?
The market values Hikal Limited at about ₹26.7B (market capitalisation, as of Nov 11, 2026). Per share that is ₹216.58; our models calculate a fair value of ₹23.70 per share.
What do the bullish and bearish scenarios say about HIKAL?
Our models span a range for Hikal Limited: cautious scenario ₹23.70, base ₹23.70, optimistic ₹43.21 per share (as of Nov 11, 2026, price ₹216.58). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hikal Limited (HIKAL)?
Balance-sheet figures for Hikal Limited (as of Nov 11, 2026): return on equity −0.4%, debt of 0.31 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is HIKAL from its 52-week high?
Hikal Limited trades at ₹216.58, about 15% below its 52-week high of ₹255.48 and 47% above the low of ₹146.84 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹23.70 is for.
Which stocks are comparable to Hikal Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hikal Limited stock attractive at the current price?
The data as of Nov 11, 2026: price ₹216.58, calculated fair value ₹23.70 (−89%), Quality Score 42/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HIKAL calculated?
We run Hikal Limited through 14 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of ₹23.70 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Hikal Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hikal Limited (HIKAL)?
The closing price on Nov 16, 2026 was ₹216.58. Our model-based fair value is ₹23.70, about 89% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hikal Limited right now?
The price sits above even our optimistic bull case (₹43.21). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹23.70 to ₹43.21) leaves room in how you read the outcome.
Where does the earnings growth of Hikal Limited (HIKAL) come from?
Earnings per share at Hikal Limited grew 5.8 % a year from 2015 to 2026. Broken into its drivers: revenue per share +8.1 %, EBIT margin +16.6 %, tax rate −0.6 %, residual (interest, one-offs) −15.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Hikal Limited

How large is the market capitalisation of Hikal Limited (HIKAL)?
The market capitalisation of Hikal Limited is ₹26.7B (≈ $284M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Hikal Limited (HIKAL) excluding one-off items?
Excluding one-off items, the price-to-earnings ratio of Hikal Limited is 629.8 (fiscal year 2026, the reported result was a loss, median at FY-end 37.6 (8 FY)).
What is the P/S ratio of Hikal Limited (HIKAL)?
The price-to-sales ratio of Hikal Limited is 1.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hikal Limited (HIKAL)?
Earnings per share at Hikal Limited are ₹−2.74. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hikal Limited (HIKAL)?
The dividend yield of Hikal Limited is 0.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hikal Limited (HIKAL)?
The net margin of Hikal Limited is −0.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hikal Limited (HIKAL)?
The return on equity (ROE) of Hikal Limited is −0.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hikal Limited (HIKAL)?
On an EBIT basis the return on assets of Hikal Limited is 11.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hikal Limited (HIKAL)?
The operating margin of Hikal Limited is 0.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hikal Limited (HIKAL)?
Revenue at Hikal Limited is growing 36.3% versus a year earlier (3y avg −5.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hikal Limited (HIKAL)?
Earnings per share at Hikal Limited are growing 68.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hikal Limited (HIKAL) carry?
The net debt of Hikal Limited is ₹6.7B (fiscal year 2026, ≈ 7.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Hikal Limited in the live analysis

One click puts Hikal Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.